Depending on how one views it, the stock price performance for the year has been a mixed bag, resulting in either an optimistic or pessimistic outlook. The metric has seen a significant loss of -49.93% since the start of this calendar year. Looking back over the last six months, we can see a stronger performance of -45.95%. Over the past 30 days, the price of DAWN has leaped by -2.58%. And in the last five days, it has surged by 4.94%.
Day One Biopharmaceuticals Inc experienced a rather shaky stock market performance. The highest value in the past year was recorded at $16.76 on 11/08/24 and the lowest value was $6.08 on 05/16/25.
52-week price history of DAWN Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Day One Biopharmaceuticals Inc’s current trading price is -59.43% away from its 52-week high, while its distance from the 52-week low is 11.84%. The stock’s price range during this period has varied between$6.08 and $16.76. The Day One Biopharmaceuticals Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.45 million for the day, a figure considerably lower than their average daily volume of 1.37 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Day One Biopharmaceuticals Inc (DAWN) has experienced a quarterly decline of -14.68% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 689.27M and boasts a workforce of 181 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
DAWN’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for DAWN stands at 0.01. Similarly, the long-term debt-to-equity ratio is also 0.01.
